Ticker Details
Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
IPO Date:	October 1, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$290.23M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.59 | 4.00%
Avg Daily Range (30 D):	$0.11 | 4.50%
Avg Daily Range (90 D):	$0.11 | 5.72%

Institutional Daily Volume
Avg Daily Volume:	.98M
Avg Daily Volume (30 D):	2.97M
Avg Daily Volume (90 D):	3M

Trade Size
Avg Trade Size (Sh.):	124
Avg Trade Size (Sh.) (30 D):	210
Avg Trade Size (Sh.) (90 D):	249

Institutional Trades
Total Institutional Trades:	3,491
Avg Institutional Trade:	$2.73M
Avg Institutional Trade (30 D):	$2.09M
Avg Institutional Trade (90 D):	$1.62M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.78M
Avg Closing Trade (30 D):	$2.67M
Avg Closing Trade (90 D):	$2.07M
Avg Closing Volume:	211.86K

News

Jun 10, 2026 @ 5:00 PM Lupus Nephritis Clinical Trial Landscape Becomes I... Source: Delveinsight

May 20, 2026 @ 1:50 PM Cell-Based Therapies Poised to Disrupt Multi-Billi... Source: Market News Updates

Mar 27, 2026 @ 1:15 PM Scalable Biotech Manufacturing Unlocks a $14B Mark... Source: Usanewsgroup.Com News Commentary

Mar 3, 2026 @ 3:02 PM Cell Therapies Moving From Lab to Factory Floor, a... Source: Prnewswire

Feb 16, 2026 @ 6:00 PM IPSC-derived NK Cells Clinical Trial Pipeline Gain... Source: Delveinsight

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.09	$-.26	$-.27
Diluted EPS	$-1.09	$-.26	$-.27
Revenue	$6.32M	$1.3M	$1.37M
Gross Profit
Net Income / Loss	$-129.91M	$-31.21M	$-32.37M
Operating Income / Loss	$-139.42M	$-33M	$-34.72M
Cost of Revenue
Net Cash Flow	$10.57M	$M	$6.01M
PE Ratio